{"id":"https://openalex.org/W2167093651","doi":"https://doi.org/10.1080/02841860601096841","title":"Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis","display_name":"Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis","publication_year":2006,"publication_date":"2006-12-19","ids":{"openalex":"https://openalex.org/W2167093651","doi":"https://doi.org/10.1080/02841860601096841","mag":"2167093651","pmid":"https://pubmed.ncbi.nlm.nih.gov/17453363"},"language":"en","primary_location":{"id":"doi:10.1080/02841860601096841","doi":"https://doi.org/10.1080/02841860601096841","is_oa":true,"landing_page_url":"https://doi.org/10.1080/02841860601096841","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/02841860601096841?needAccess=true&role=button","source":{"id":"https://openalex.org/S1043257","display_name":"Acta Oncologica","issn_l":"0284-186X","issn":["0284-186X","1651-226X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Acta Oncologica","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.tandfonline.com/doi/pdf/10.1080/02841860601096841?needAccess=true&role=button","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025585146","display_name":"Jan Norum","orcid":"https://orcid.org/0000-0001-9341-3506","observed_orcids":["https://orcid.org/0000-0001-9341-3506"]},"institutions":[{"id":"https://openalex.org/I1298853749","display_name":"University Hospital of North Norway","ror":"https://ror.org/030v5kp38","country_code":"NO","type":"healthcare","lineage":["https://openalex.org/I1298853749","https://openalex.org/I63903255"]},{"id":"https://openalex.org/I78037679","display_name":"UiT The Arctic University of Norway","ror":"https://ror.org/00wge5k78","country_code":"NO","type":"education","lineage":["https://openalex.org/I78037679"]}],"countries":["NO"],"is_corresponding":true,"raw_author_name":"J. Norum","raw_affiliation_strings":["Department of Oncology, University Hospital of North Norway, Troms\u00f8, Norway. jan.norum@unn.no","Department of Oncology, University Hospital of North Norway, Troms\u00f8, Norway","Institute of Clinical Medicine, University of Troms\u00f8, Troms\u00f8, Norway"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, University Hospital of North Norway, Troms\u00f8, Norway. jan.norum@unn.no","institution_ids":["https://openalex.org/I1298853749"]},{"raw_affiliation_string":"Department of Oncology, University Hospital of North Norway, Troms\u00f8, Norway","institution_ids":["https://openalex.org/I1298853749"]},{"raw_affiliation_string":"Institute of Clinical Medicine, University of Troms\u00f8, Troms\u00f8, Norway","institution_ids":["https://openalex.org/I78037679"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052181611","display_name":"Jan Abel Olsen","orcid":"https://orcid.org/0000-0001-9472-2669","observed_orcids":["https://orcid.org/0000-0001-9472-2669"]},"institutions":[{"id":"https://openalex.org/I184942183","display_name":"University of Oslo","ror":"https://ror.org/01xtthb56","country_code":"NO","type":"education","lineage":["https://openalex.org/I184942183"]},{"id":"https://openalex.org/I78037679","display_name":"UiT The Arctic University of Norway","ror":"https://ror.org/00wge5k78","country_code":"NO","type":"education","lineage":["https://openalex.org/I78037679"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"J. A. Olsen","raw_affiliation_strings":["Institute of Community Medicine, University of Troms\u00f8, Troms\u00f8, Norway; Health Economics Research Programme, University of Oslo, Oslo, Norway","Health Economics Research Programme, University of Oslo, Oslo, Norway","Institute of Community Medicine, University of Troms\u00f8, Troms\u00f8, Norway"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Community Medicine, University of Troms\u00f8, Troms\u00f8, Norway; Health Economics Research Programme, University of Oslo, Oslo, Norway","institution_ids":["https://openalex.org/I184942183","https://openalex.org/I78037679"]},{"raw_affiliation_string":"Health Economics Research Programme, University of Oslo, Oslo, Norway","institution_ids":["https://openalex.org/I184942183"]},{"raw_affiliation_string":"Institute of Community Medicine, University of Troms\u00f8, Troms\u00f8, Norway","institution_ids":["https://openalex.org/I78037679"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113126986","display_name":"E. Wist","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1281400175","display_name":"Oslo University Hospital","ror":"https://ror.org/00j9c2840","country_code":"NO","type":"healthcare","lineage":["https://openalex.org/I1281400175"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"E. A. Wist","raw_affiliation_strings":["Department of Oncology, Ullev\u00e5l University Hospital, Oslo, Norway"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Ullev\u00e5l University Hospital, Oslo, Norway","institution_ids":["https://openalex.org/I1281400175"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5035837487","display_name":"Per Eystein L\u00f8nning","orcid":"https://orcid.org/0000-0002-8890-6303","observed_orcids":["https://orcid.org/0000-0002-8890-6303"]},"institutions":[{"id":"https://openalex.org/I4432739","display_name":"University of Bergen","ror":"https://ror.org/03zga2b32","country_code":"NO","type":"education","lineage":["https://openalex.org/I4432739"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"P. E. L\u00f8nning","raw_affiliation_strings":["Section of Oncology, Institute of Internal Medicine, University of Bergen, Norway"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Oncology, Institute of Internal Medicine, University of Bergen, Norway","institution_ids":["https://openalex.org/I4432739"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5025585146"],"corresponding_institution_ids":["https://openalex.org/I1298853749","https://openalex.org/I78037679"],"apc_list":null,"apc_paid":null,"fwci":11.1501,"has_fulltext":true,"cited_by_count":49,"citation_normalized_percentile":{"value":0.9795479,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"46","issue":"2","first_page":"153","last_page":"164"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":1.0},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.8980000019073486},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9399999976158142},{"id":"https://openalex.org/keywords/health-economic-models","display_name":"health economic models","score":0.4569999873638153},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6480000019073486},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8230000138282776},{"id":"https://openalex.org/keywords/cost-per-quality-adjusted-life-year","display_name":"cost per quality-adjusted life year","score":0.7940000295639038},{"id":"https://openalex.org/keywords/fec-regimen","display_name":"FEC regimen","score":0.5690000057220459},{"id":"https://openalex.org/keywords/social-costs","display_name":"social costs","score":0.6690000295639038},{"id":"https://openalex.org/keywords/discount-rate","display_name":"discount rate","score":0.5519999861717224},{"id":"https://openalex.org/keywords/norway","display_name":"Norway","score":0.3269999921321869}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9501007199287415},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.805157482624054},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6372960209846497},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6268177628517151},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.6141901612281799},{"id":"https://openalex.org/C2777982462","wikidata":"https://www.wikidata.org/wiki/Q2481887","display_name":"Adjuvant therapy","level":3,"score":0.4928903579711914},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46136942505836487},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4560295641422272},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.4000137448310852},{"id":"https://openalex.org/C19527891","wikidata":"https://www.wikidata.org/wiki/Q1120908","display_name":"Medical physics","level":1,"score":0.34996849298477173}],"mesh":[{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008017","descriptor_name":"Life Expectancy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009664","descriptor_name":"Norway","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017024","descriptor_name":"Chemotherapy, Adjuvant","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D017048","descriptor_name":"Health Care Costs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/02841860601096841","doi":"https://doi.org/10.1080/02841860601096841","is_oa":true,"landing_page_url":"https://doi.org/10.1080/02841860601096841","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/02841860601096841?needAccess=true&role=button","source":{"id":"https://openalex.org/S1043257","display_name":"Acta Oncologica","issn_l":"0284-186X","issn":["0284-186X","1651-226X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Acta Oncologica","raw_type":"journal-article"},{"id":"pmid:17453363","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17453363","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Acta oncologica (Stockholm, Sweden)","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1080/02841860601096841","doi":"https://doi.org/10.1080/02841860601096841","is_oa":true,"landing_page_url":"https://doi.org/10.1080/02841860601096841","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/02841860601096841?needAccess=true&role=button","source":{"id":"https://openalex.org/S1043257","display_name":"Acta Oncologica","issn_l":"0284-186X","issn":["0284-186X","1651-226X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Acta Oncologica","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320320971","display_name":"Monash University","ror":"https://ror.org/02bfwt286"},{"id":"https://openalex.org/F4320337337","display_name":"National Institute on Aging","ror":"https://ror.org/049v75w11"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2167093651.pdf","grobid_xml":"https://content.openalex.org/works/W2167093651.grobid-xml"},"referenced_works_count":39,"referenced_works":["https://openalex.org/W1531300355","https://openalex.org/W1531524380","https://openalex.org/W1595046345","https://openalex.org/W1966562726","https://openalex.org/W1975455427","https://openalex.org/W1981992634","https://openalex.org/W1988025128","https://openalex.org/W1988674313","https://openalex.org/W2002123282","https://openalex.org/W2007256480","https://openalex.org/W2043951092","https://openalex.org/W2078268211","https://openalex.org/W2089190823","https://openalex.org/W2095156669","https://openalex.org/W2105189307","https://openalex.org/W2108410343","https://openalex.org/W2113676600","https://openalex.org/W2121271793","https://openalex.org/W2122142036","https://openalex.org/W2125955497","https://openalex.org/W2126012768","https://openalex.org/W2127027500","https://openalex.org/W2127815244","https://openalex.org/W2128039037","https://openalex.org/W2131994307","https://openalex.org/W2136166098","https://openalex.org/W2140618548","https://openalex.org/W2141393790","https://openalex.org/W2142454772","https://openalex.org/W2144124503","https://openalex.org/W2146384083","https://openalex.org/W2149908785","https://openalex.org/W2156108617","https://openalex.org/W2170369073","https://openalex.org/W2226378560","https://openalex.org/W2318605753","https://openalex.org/W2590475106","https://openalex.org/W4234914873","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2105189307","https://openalex.org/W2272557138","https://openalex.org/W2059170159","https://openalex.org/W2101341097","https://openalex.org/W7098679313","https://openalex.org/W2139107075","https://openalex.org/W4398764825","https://openalex.org/W2113167936","https://openalex.org/W2392848697","https://openalex.org/W2100717480"],"abstract_inverted_index":{"Trastuzumab":[0,160],"has":[1],"shown":[2],"activity":[3],"in":[4,62,165],"early":[5],"breast":[6],"cancer":[7],"patients":[8],"that":[9],"overexpress":[10],"HER2.":[11],"Significant":[12],"resources":[13],"have":[14],"to":[15,18,54,152],"be":[16,153],"allocated":[17],"finance":[19],"this":[20],"therapy,":[21],"underlining":[22],"the":[23,38,49,69,129,154],"need":[24],"for":[25],"cost-effectiveness":[26,158],"analysis.":[27],"A":[28],"model":[29],"was":[30,41,68,81,92,119],"set":[31],"up,":[32],"societal":[33],"costs":[34],"were":[35,46,131],"calculated":[36],"and":[37,51,58,100,122,134,149],"discount":[39,150],"rate":[40,151],"3%.":[42],"Life":[43],"expectancy":[44],"data":[45],"based":[47],"on":[48],"literature":[50],"prolonged":[52],"according":[53],"qualified":[55],"guess":[56],"(10%":[57],"20%":[59,97],"absolute":[60],"improvement":[61],"overall":[63],"survival":[64,142],"(OS)).":[65],"The":[66,72,84,107],"comparator":[67],"FEC(100)":[70],"regimen.":[71],"median":[73],"additional":[74],"health":[75,110],"care":[76,111],"cost":[77,86,112,163],"per":[78,87,113,137],"patient":[79],"treated":[80],"33,597":[82],"euros.":[83,124],"yielding":[85],"life":[88,116],"year":[89,117],"gained":[90],"(LYG)":[91],"15,341":[93],"euros":[94,102,121,133,136],"with":[95,103],"a":[96],"improved":[98,105],"OS":[99],"35,947":[101],"10%":[104],"OS.":[106],"corresponding":[108],"net":[109],"quality":[114],"adjusted":[115],"(QALY)":[118],"19,176":[120],"44,934":[123],"Including":[125],"all":[126],"resource":[127],"use":[128],"figures":[130],"8148":[132],"30,290":[135],"LYG.":[138],"Sensitivity":[139],"analyses":[140],"documented":[141],"gain,":[143],"price":[144],"of":[145],"trastuzumab,":[146],"production":[147],"gain":[148],"major":[155],"factors":[156],"influencing":[157],"ratio.":[159],"is":[161],"indicated":[162],"effective":[164],"Norway.":[166]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}